01 September 2008

Lords add to obviousness debate

The House of Lords made its most important patent ruling in recent times when it clarified the test for obviousness in the UK. How have other courts dealt with this issue?

The House of Lords made its most important patent ruling in recent times on July 9, when it clarified the test for obviousness in the UK. In the closely watched case, Conor Medsystems Inc v Angiotech Pharmaceuticals Inc, the Lords upheld the validity of Angiotech's European patent for a paclitaxel-eluting stent and reversed the decisions of the UK Court of First Instance and the Court of Appeal. The lower courts had held the European patent to be invalid on the grounds of obviousness, though the validity of the same patent had been upheld in proceedings in The Netherlands.

The rest of this article is available to subscribers to Managing IP only.

Managing IP subscribers also have access to Managing Patents, Trade marks and Copyright until 30th October 2010.
Managing IP trialists have access to Managing Patents, Trade marks and Copyright for 48-hours.

Subscribe today for full access to this article. Alternatively, take a 48-hour free trial giving you access to the current content.

If you are already a subscriber please log in (see top right column) to access the rest of this article.

Managing Intellectual Property

Navigation Menu

Managing IP Home Page

Managing IP Products

Browse Magazine

IP Resources

Lords add to obviousness debate

The rest of this article is available to subscribers to Managing IP only.

Events